Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02162 KEYMED BIO-B > Main Composition
02162 KEYMED BIO-B
49.050
-1.800-3.54%
All
YOY
Do not show
Business Unit:CNY

Loading...

Product

Loading...

Region

Loading...

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

Company Overview More
Konoya Biopharmaceutical Technology Co., Ltd. is a biotechnology company with a variety of clinical assets, each of which is a strong competitor in its respective competitive field. We focus on finding and developing innovative biotherapies to meet a large number of unmet medical needs in the field of autoimmunity and oncology therapy. With a strong foundation in biomedical research, we have mastered in-house drug discovery and development technologies, including our innovative antibody discovery platform and our own novel T cell redirection (nTCE) bispecific antibody platform. In less than five years since its establishment, we have consistently explored areas of disease treatment that are extremely challenging and in short supply. Now, we have more than ten drug candidates in the internal development stage, five of which are in the clinical stage. Our own products under research and development apply cutting-edge scientific discoveries and reflect our profound market insight. Health spending increased significantly in the first two decades of the new millennium driven by economic growth and the reform of the health care system. Due to the rapid development of urbanization, changes in residents' lifestyle and environmental changes, China's epidemiological focus is shifting from the prevalence of infectious diseases to the prevalence of cancer and other chronic diseases. These basic and evolving trends pose new challenges to public health and expose new areas of disease that are heavily burdened by inadequate treatments. To support our innovative research and development of biopharmaceuticals, we have established a fully integrated platform covering all key functions of biopharmaceutical development, including target verification, lead compound generation and optimization, preclinical evaluation, process development, transformation research, clinical development and production. This integrated platform enables us to quickly and cost-effectively discover, build, expand and advance our diversified pipeline of innovative and differentiated antibody therapy, including monoclonal antibodies, antibody-coupled drugs and bispecific antibodies.
CEO: Bo CHEN
Market: Hong Kong motherboard
Listing Date: 07/08/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist